Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Amortizatization of Intangibles: 2018-2024

Historic Amortizatization of Intangibles for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to $8.3 million.

  • Allogene Therapeutics' Amortizatization of Intangibles fell 45.67% to $923,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 49.47%. This contributed to the annual value of $8.3 million for FY2024, which is 22.60% up from last year.
  • Allogene Therapeutics' Amortizatization of Intangibles amounted to $8.3 million in FY2024, which was up 22.60% from $6.8 million recorded in FY2023.
  • Allogene Therapeutics' Amortizatization of Intangibles' 5-year high stood at $8.3 million during FY2024, with a 5-year trough of -$7.0 million in FY2021.
  • In the last 3 years, Allogene Therapeutics' Amortizatization of Intangibles had a median value of $6.8 million in 2023 and averaged $4.1 million.
  • As far as peak fluctuations go, Allogene Therapeutics' Amortizatization of Intangibles crashed by 190.38% in 2020, and later skyrocketed by 335.52% in 2023.
  • Over the past 5 years, Allogene Therapeutics' Amortizatization of Intangibles (Yearly) stood at -$3.2 million in 2020, then tumbled by 114.00% to -$7.0 million in 2021, then soared by 58.43% to -$2.9 million in 2022, then soared by 335.52% to $6.8 million in 2023, then climbed by 22.60% to $8.3 million in 2024.